Gilead Sciences NASDAQ: GILD has filed 13-F forms with the SEC as an investor. Gilead Sciences is itself a publicly traded company. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. For more information on Gilead Sciences stock, visit the Gilead Sciences stock profile here.
Investment Activity
- Gilead Sciences has $2.12 billion in total holdings as of March 31, 2026.
- Gilead Sciences owns shares of 6 different stocks, but just 3 companies or ETFs make up 80% of its holdings.
- About 3.36% of the portfolio was sold this quarter.
- This quarter, Gilead Sciences has purchased 6 new stocks and bought additional shares in 0 stocks.
- Gilead Sciences sold shares of 1 stock and completely divested from 0 stocks this quarter.
Largest Holdings
- Galapagos NV
- $501,224,310
- Assembly Biosciences Inc
- $125,024,600
- Kyverna Therapeutics Inc
- $35,608,407
Largest Sales this Quarter
